Luomalla maksuttoman Inderes-tilin, pääset käsiksi Inderesin analyysiin, voit tilata suositun aamukatsauksen ja seurata sinua kiinnostavia yhtiöitä sekä keskusteluita.
Onko sinulla jo Inderes-tili?
Follow this company like 3893 other investors.
Redeye endorses today’s news that Herantis has submitted a clinical trial application for a phase I study with its lead candidate HER-096 targeting Parkinson’s disease.
Redeye comments on yesterday’s H1 report from Herantis and we reiterate our view of the company.
Redeye has a positive take on the news that Antti Vuolanto, currently COO, has been named as CEO of Herantis.
Redeye comments on the recent news in the company and adjust for the recent capital injections in the company.
Redeye comments on the news that Herantis has carried out a directed issue and announced the intention to carry out a rights issue worth in total EUR 8.7 million.
Redeye comments on the H2 report from Herantis Pharma and reiterate our view of the company.
Redeye comments on yesterday’s CEO change in Herantis and announcement of strategy shift towards its next generation xCDNF program.
Redeye has an overall positive take on the progress presented at yesterday’s R&D Seminar. We give our view of the way forward for Herantis lead projects addressing Parkinson’s Disease (rhCDNF and HER-096).
Redeye comments on yesterday’s directed share issue of EUR 4 million.
Summary of events in H1’21Updated model following refocusing on CNSUpcoming milestonesDuring H1’21, Herantis decided to focus all resources on its CDNF and xCDNF assets and not pursue further development of Lymfactin, instead seeking to out-license t
